Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PDE (phosphodiesterase)4 inhibitor

A technology of phosphodiesterase and inhibitors, which is applied in the field of medicine, can solve problems such as undisclosed uses, and achieve the effect of repairing degenerative changes

Inactive Publication Date: 2017-12-01
兰晟生物医药(苏州)有限公司
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This compound has been disclosed in the prior art, see Development of highly potent phosphodiesterase4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. Eur J Med Chem. 2016;124:372- 379. However, its use in the treatment of Parkinson's disease is not disclosed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PDE (phosphodiesterase)4 inhibitor
  • Application of PDE (phosphodiesterase)4 inhibitor
  • Application of PDE (phosphodiesterase)4 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments.

[0024] A kind of application of phosphodiesterase 4 inhibitor, phosphodiesterase 4 inhibitor is FCPR16, and its structural formula is:

[0025] ;

[0026] FCPR16 is used in drugs for preventing or treating Parkinson's disease. Or it can be used in the preparation of medicines for repairing dopaminergic neuron damage; the prepared medicines can be used for repairing degeneration or cell apoptosis or oxidative damage of dopaminergic neurons.

[0027] In an embodiment, the medicament contains the FCPR16 compound or a pharmaceutically acceptable salt thereof.

[0028] In an embodiment, the drug is administered in the form of injection, oral preparation or external preparation.

[0029] In an embodiment, the preparation form of the medicine includes tablet, capsule, powder, pill, granule, injection or emulsion.

[0030] The following experime...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a PDE (phosphodiesterase)4 inhibitor. The PDE4 inhibitor is FCPR16, and the structural formula of the inhibitor is represented in the description; FCPR16 is applied to preparation of drugs for preventing or treating PD (Parkinson's disease) or applied to preparation of drugs for repairing dopaminergic neuron damage. The application of the inhibitor in preparation of drugs for treating PD is disclosed for the first time, the new application field of the PDE4D inhibitor FCPR16 is expanded, and the inhibitor has good effect on dyskinesia of PD; the inhibitor can repair retrogression, apoptosis or oxidative damage of dopaminergic neurons.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a phosphodiesterase 4 inhibitor. Background technique [0002] Parkinson's disease (PD) is a degenerative disease of the central nervous system, which mostly occurs in the middle-aged and elderly people. With the aging of the social population, PD has seriously affected the quality of life of the patients themselves and their families. influences. The main pathological feature of the disease is the progressive loss of dopamine neurons in the substantia nigra, which further leads to a decrease in dopamine content in the striatum. The exact mechanism leading to this disease has not yet been clarified. Existing studies generally believe that it is related to environmental factors, mitochondrial dysfunction, genetic factors, oxidative stress, gene mutation, neurotoxicity, inflammation, and autophagy, and it may also be caused by multiple factors. Result of joint...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/167A61P25/16A61P25/14A61P25/00
CPCA61K31/167
Inventor 徐澜迪
Owner 兰晟生物医药(苏州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com